These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 23364775)

  • 1. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes.
    Carlquist JF; Knight S; Horne BD; Huntinghouse JA; Rollo JS; Muhlestein JB; May H; Anderson JL
    Thromb Haemost; 2013 Apr; 109(4):744-54. PubMed ID: 23364775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects.
    Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W
    Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
    Wallentin L; James S; Storey RF; Armstrong M; Barratt BJ; Horrow J; Husted S; Katus H; Steg PG; Shah SH; Becker RC;
    Lancet; 2010 Oct; 376(9749):1320-8. PubMed ID: 20801498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of response to clopidogrel and cardiovascular events.
    Simon T; Verstuyft C; Mary-Krause M; Quteineh L; Drouet E; Méneveau N; Steg PG; Ferrières J; Danchin N; Becquemont L;
    N Engl J Med; 2009 Jan; 360(4):363-75. PubMed ID: 19106083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
    Wu H; Qian J; Sun A; Wang Q; Ge J
    Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel.
    Luo Y; Zhao YT; Verdo A; Qi WG; Zhang DF; Hu B
    J Int Med Res; 2011; 39(5):2012-9. PubMed ID: 22118006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
    Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of platelet pharmacogenetics in common clinical practice of patients with ST-segment elevation myocardial infarction.
    Verschuren JJ; Boden H; Wessels JA; van der Hoeven BL; Trompet S; Heijmans BT; Putter H; Guchelaar HJ; Schalij MJ; Jukema JW
    Int J Cardiol; 2013 Sep; 167(6):2882-8. PubMed ID: 22940005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.
    Trenk D; Hochholzer W; Fromm MF; Chialda LE; Pahl A; Valina CM; Stratz C; Schmiebusch P; Bestehorn HP; Büttner HJ; Neumann FJ
    J Am Coll Cardiol; 2008 May; 51(20):1925-34. PubMed ID: 18482659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
    Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
    JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
    Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events.
    Tiroch KA; Sibbing D; Koch W; Roosen-Runge T; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2010 Sep; 160(3):506-12. PubMed ID: 20826260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of clopidogrel.
    O'Connor SA; Hulot JS; Silvain J; Cayla G; Montalescot G; Collet JP
    Curr Pharm Des; 2012; 18(33):5309-27. PubMed ID: 22724417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel.
    Sawada T; Shinke T; Shite J; Honjo T; Haraguchi Y; Nishio R; Shinohara M; Toh R; Ishida T; Kawamori H; Kozuki A; Inoue T; Hariki H; Hirata K
    Circ J; 2011; 75(1):99-105. PubMed ID: 21099121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.